The Montreal Cognitive Assessment (MoCA) in neuro-oncology: A pilot study of feasibility and utility in telehealth and in-person clinical assessments.
CNS tumors
cognitive dysfunction
neurocognitive testing
telehealth
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
entrez:
20
9
2022
pubmed:
21
9
2022
medline:
21
9
2022
Statut:
epublish
Résumé
Cognitive impairments are a common burden for patients with primary CNS tumors. Neuropsychological assessment batteries can be too lengthy, which limits their use as an objective measure of cognition during routine care. The purpose of this study was to evaluate the feasibility and utility of the brief Montreal Cognitive Assessment (MoCA) in routine in-person and telehealth visits (as a result of the global COVID-19 pandemic) with neuro-oncology patients. Seventy-one adults with primary CNS tumors completed MoCA testing in person (n = 47) and via telehealth (n = 24). Correlation analysis and patient-reported outcomes (PROs), including symptom burden and interference, perceived cognition, general health status, and anxiety and depression, were included in this study. Feasibility was assessed through a provider satisfaction questionnaire. Patients were primarily White (83%), college-educated (71%) males (54%) with high-grade tumors (66%). The average total score on the MoCA administered in person was 25 (range: 6-30), with 34% classified as abnormal, and the average total score via telehealth was 26 (range: 12-30), with 29% classified as abnormal. Providers reported satisfaction in using the MoCA during routine clinical care, both in person and via telehealth. Lower MoCA scores correlated with worse symptom severity, KPS, age, education, and previous treatment. The MoCA was feasible in clinical and telehealth settings, and its relationship to clinical characteristics and PROs highlights the need for both objective and patient-reported measures of cognition to understand the overall cognitive profile of a patient with a CNS tumor.
Sections du résumé
Background
UNASSIGNED
Cognitive impairments are a common burden for patients with primary CNS tumors. Neuropsychological assessment batteries can be too lengthy, which limits their use as an objective measure of cognition during routine care. The purpose of this study was to evaluate the feasibility and utility of the brief Montreal Cognitive Assessment (MoCA) in routine in-person and telehealth visits (as a result of the global COVID-19 pandemic) with neuro-oncology patients.
Methods
UNASSIGNED
Seventy-one adults with primary CNS tumors completed MoCA testing in person (n = 47) and via telehealth (n = 24). Correlation analysis and patient-reported outcomes (PROs), including symptom burden and interference, perceived cognition, general health status, and anxiety and depression, were included in this study. Feasibility was assessed through a provider satisfaction questionnaire.
Results
UNASSIGNED
Patients were primarily White (83%), college-educated (71%) males (54%) with high-grade tumors (66%). The average total score on the MoCA administered in person was 25 (range: 6-30), with 34% classified as abnormal, and the average total score via telehealth was 26 (range: 12-30), with 29% classified as abnormal. Providers reported satisfaction in using the MoCA during routine clinical care, both in person and via telehealth. Lower MoCA scores correlated with worse symptom severity, KPS, age, education, and previous treatment.
Conclusions
UNASSIGNED
The MoCA was feasible in clinical and telehealth settings, and its relationship to clinical characteristics and PROs highlights the need for both objective and patient-reported measures of cognition to understand the overall cognitive profile of a patient with a CNS tumor.
Identifiants
pubmed: 36124322
doi: 10.1093/nop/npac038
pii: npac038
pmc: PMC9384084
doi:
Types de publication
Journal Article
Langues
eng
Pagination
429-440Informations de copyright
Published by Oxford University Press 2022.
Références
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
Hematol Oncol Clin North Am. 2022 Feb;36(1):269-282
pubmed: 34711455
Arch Clin Neuropsychol. 2017 Jun 1;32(4):491-498
pubmed: 28334244
Neurol Sci. 2020 Nov;41(11):3105-3121
pubmed: 32656714
Neuro Oncol. 2016 Feb;18(2):252-60
pubmed: 26289592
Phys Med Rehabil Clin N Am. 2020 Aug;31(3):345-368
pubmed: 32624099
Neuro Oncol. 2011 Jun;13(6):660-8
pubmed: 21558074
Neurosurgery. 2000 Aug;47(2):324-33; discussion 333-4
pubmed: 10942005
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Acta Neurochir (Wien). 2020 Apr;162(4):803-812
pubmed: 31993749
Biomed Res Int. 2020 Dec 09;2020:6692802
pubmed: 33376730
J Am Geriatr Soc. 2013 Dec;61(12):2181-2185
pubmed: 24320735
World Neurosurg. 2019 Feb;122:e1551-e1556
pubmed: 30471447
J Neurotrauma. 2017 Mar 15;34(6):1156-1163
pubmed: 27717295
Cogn Behav Neurol. 2021 Dec 2;34(4):245-258
pubmed: 34508028
Support Care Cancer. 2008 Nov;16(11):1273-8
pubmed: 18335256
J Neurooncol. 2017 Aug;134(1):9-18
pubmed: 28567586
J Neurooncol. 2006 Oct;80(1):27-35
pubmed: 16598415
Curr Oncol Rep. 2019 May 2;21(6):55
pubmed: 31049786
Aging Clin Exp Res. 2022 Jul;34(7):1627-1633
pubmed: 35178685
Health Informatics J. 2016 Jun;22(2):304-11
pubmed: 25391849
Neurology. 2009 Nov 24;73(21):1738-45
pubmed: 19933974
J Clin Neurosci. 2018 Jul;53:79-84
pubmed: 29685411
Acta Oncol. 2019 May;58(5):745-752
pubmed: 30757955
Front Oncol. 2015 Mar 11;5:60
pubmed: 25815273
J Neurosurg Spine. 2010 Apr;12(4):421-30
pubmed: 20367379
Neurology. 2014 Jul 22;83(4):320-7
pubmed: 24944262
Clin Neurol Neurosurg. 2017 Dec;163:18-23
pubmed: 29035741
Front Neurol. 2020 Dec 08;11:591615
pubmed: 33363506
Telemed J E Health. 2020 Jul;26(7):920-928
pubmed: 31746697
Neurology. 2012 Jun 5;78(23):1860-7
pubmed: 22573626
J Telemed Telecare. 2021 Sep;27(8):484-492
pubmed: 31813317
Assessment. 2011 Sep;18(3):263-83
pubmed: 21697139
Curr Neurol Neurosci Rep. 2010 May;10(3):232-9
pubmed: 20425039
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Cochrane Database Syst Rev. 2019 Aug 05;8:CD013047
pubmed: 31425631
J Clin Oncol. 2003 Oct 1;21(19):3557-8
pubmed: 12913103